Januvia vs Mounjaro
Side-by-side cost comparison based on Medicare Part D data
Januvia
Sitagliptin
Manufactured by Merck
Mounjaro
Tirzepatide
Manufactured by Eli Lilly
Januvia costs 67% less per claim than Mounjaro ($219.00 vs $673.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Januvia | Mounjaro |
|---|---|---|
| Avg Cost Per Claim | $219.00 | $673.00 |
| Total Medicare Spending | $2.7B | $2.5B |
| Total Beneficiaries | 1,560,000 | 524,000 |
| Total Claims | 12,480,000 | 3,680,000 |
| Annual Cost/Patient | $1,753.00 | $4,729.00 |
| Year-over-Year Change | -12.3% | +312.4% |
| Generic Available | No | No |
| Patent Expiration | Jul 17, 2026 | May 13, 2036 |
| Manufacturer | Merck | Eli Lilly |
| Condition | Diabetes | Diabetes |
| Generic Name | Sitagliptin | Tirzepatide |
Januvia vs Mounjaro: What the Data Shows
Januvia (Sitagliptin) and Mounjaro (Tirzepatide) are both used to treat diabetes. Based on Medicare Part D data, Januvia costs $219.00 per claim, which is 67% less than Mounjaro at $673.00 per claim.
Medicare spent $2.7B on Januvia and $2.5B on Mounjaro. In terms of patient reach, Januvia serves more beneficiaries (1,560,000 vs 524,000).
Year-over-year spending changed -12.3% for Januvia and +312.4% for Mounjaro. Mounjaro saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Januvia patent expires Jul 17, 2026. Mounjaro patent expires May 13, 2036.
Frequently Asked Questions
Januvia is cheaper at $219.00 per claim, compared to $673.00 for Mounjaro. That makes Januvia about 67% less expensive per claim based on Medicare Part D data.
Yes, both Januvia and Mounjaro are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Januvia patent expires Jul 17, 2026. Mounjaro patent expires May 13, 2036.
Medicare Part D spent $2.7B on Januvia covering 1,560,000 beneficiaries, and $2.5B on Mounjaro covering 524,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.